ESSA Pharma Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-21. 1 holder's latest filing reports 5% or more of common shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.8% | 4,362,026 | SCHEDULE 13D/A, 2025-07-21 | 2025-07-17 |
| Morgan Stanley | 4% | 1,904,062 | SCHEDULE 13G/A, 2025-10-07 | 2025-09-30 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13D/A, 2025-10-14 | 2025-10-09 |
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
Item 4 is hereby amended to add the following: Effective October 9, 2025, the Issuer was acquired by Xeno Acquisition Corp. (the "Purchaser") pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the "Parent"), Purchaser, a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025 and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding Shares in exchange for: (i) $0.124231 in cash per Share (excluding the approximately $1.69 of cash per Share previously distributed to the Issuer's shareholders) and (ii) one contingent value right per Share for potential cash payments of up to approximately $0.14 per Share. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-10-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | Soleus Capital Master Fund, L.P. | 9.8% | SCHEDULE 13D/A |
| 2025-07-30 | Tang Capital Management, LLC | 9.7% | SCHEDULE 13G |
| 2025-08-07 | Biotechnology Value Fund L P | 24.7% | SCHEDULE 13D/A |
| 2025-10-07 | Morgan Stanley | 4% | SCHEDULE 13G/A |
| 2025-10-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13D/A |
| 2025-11-14 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for ESSA Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.